AIMS Award from Atomwise

Some big news about tiny molecules: cc-TDI has recently been awarded an AIMS Award from Atomwise to create a molecularly-designed new drug for EWSR1 fusion sarcomas of children and adults. Relevant cancers include difficult-to-treat diseases such as Ewing’s Sarcoma, Clear Cell Sarcoma and Sclerosing Epithelioid Fibrosarcoma. The intent is to create a small molecule that interferes with the central driving gene of these sarcomas, hopefully leading to an effective new treatment.